This study looked at the efficacy and safety through 5 years of treatment with Cosentyx (secukinumab) for psoriasis.

Quote:

---

Background:
Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favorable safety profile in the treatment of moderate to severe psoriasis and psoriatic arthritis.

Objective:
To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate to severe psoriasis.

Methods:
In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Thereafter, patients entered the extension phase and continued treatment as per the core trial. Treatment was double-blinded until the end of Year 3 and open-label from Year 4. Here we focus on the 300 mg fixed-interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed but multiple imputation (MI) and last observation carried forward (LOCF) techniques were also undertaken as supportive analyses.

Results:
At Year 1, 168 patients entered the extension study and at the end of Year 5, 126 patients completed 300mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%). PASI responses were consistent regardless of the analysis undertaken (as observed, MI, or LOCF). The average improvement in mean PASI was approximately 90% through 5 years compared to core study baseline. DLQI (dermatology life quality index) 0/1 response also sustained through 5 years (72.7% at Year 1 and 65.5% at Year 5). The safety profile of secukinumab remained favorable, with no cumulative or unexpected safety concerns identified.

Conclusion:
Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life through 5 years in patients with moderate to severe psoriasis. Favorable safety established in the secukinumab phase 2/3 program was maintained to 5 years.

Source: onlinelibrary.wiley.com

*Early view funding unknown.

Cosentyx (secukinumab)

That sounds quite good Fred, I have elected to stay on Stelara last week when I saw the derm but with the option of Cosentyx if the PsA gets any worse , the P is under control on Stelara and I am worried it will not be as good on Cosentyx.

(Thu-15-02-2018, 17:17 PM)D Foster Wrote: That sounds quite good Fred, I have elected to stay on Stelara last week when I saw the derm but with the option of Cosentyx if the PsA gets any worse , the P is under control on Stelara and I am worried it will not be as good on Cosentyx.

For me the psoriatic arthritis comes first. The psoriasis isn't any worse than it was with Stelara, but the psoriatic arthritis is fantastic.  

Plus you use Enstilar, I don't. But we're all different and you won't know till you try.

There is also Taltz to consider, and Tremfya isn't far behind.

I will just play it by ear Fred, I have been covered from head to toe with P and I mean from top to toe really bad three times now and had to go in hospital the last time 6 weeks before it was at level that I could cope with. I know that that is a few years ago now but the thought of the P getting as bad again outweighs the pain with the PsA so I will see how I get on.

(Thu-15-02-2018, 18:46 PM)D Foster Wrote: I will just play it by ear Fred, I have been covered from head to toe with P and I mean from top to toe really bad three times now and had to go in hospital the last time 6 weeks before it was at level that I could cope with. I know that that is a few years ago now but the thought of the P getting as bad again outweighs the pain with the PsA so I will see how I get on.

Yep been there too Mate. But for me I'm the opposite to you and not being able to move was worse than being covered in psoriasis.

At the end of the day Dave we all have to go with what we need and are comfortable and happy with. If you're happy with Stelara then I would say stick with it, the others will still be there later on if you should ever need them.

What happened with the 25% that dropped out?

(Fri-16-02-2018, 09:13 AM)Bill Wrote: What happened with the 25% that dropped out?

Sorry Bill that's all the information I have.

(Fri-16-02-2018, 11:36 AM)Fred Wrote:

(Fri-16-02-2018, 09:13 AM)Bill Wrote: What happened with the 25% that dropped out?

Sorry Bill that's all the information I have.

Could they be the double blinded ones who were not actually taking it after the initial 1st year up to end of year 3 ,I may be reading it wrong but they would be the base line settings and as they were not actually using the Cosentyx would not figure in the results as such.

Would be amazing if any of these actually lasted 5 years, I can’t seem to get past one year before my drugs fail..

(Tue-20-02-2018, 19:21 PM)Turnedlight Wrote: Would be amazing if any of these actually lasted 5 years, I can’t seem to get past one year before my drugs fail..

I got past 6 years with Stelara, so there is hope TL.

Plus you have the advantage of new Bio's coming through more often today.